In conclusion, the ratio of NK cells to Lox-1+ PMN-MDSCs in the peripheral blood mononuclear cells (PBMCs) of patients with NSCLC after the first round of nivolumab treatment was strongly correlated with treatment outcomes. This evidence concerns the gene OLR1 and non-small cell lung carcinoma.